The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Tscan Therapeutics Inc shares valued at $1,666,553 were purchased by Lynx1 Capital Management LP on May 19 ’25. At $1.20 per share, Lynx1 Capital Management LP acquired 1,388,794 shares. The insider’s holdings grew to 6,746,141 shares worth approximately $10.19 million following the completion of this transaction.
Also, Lynx1 Capital Management LP purchased 1,200,000 shares, netting a total of over 1,440,000 in proceeds. Following the buying of shares at $1.20 each, the insider now holds 7,946,141 shares.
Before that, Lynx1 Capital Management LP had added 100,000 shares to its account. In a trade valued at $290,140, the 10% Owner bought Tscan Therapeutics Inc shares for $2.90 each. Upon closing the transaction, the insider’s holdings increased to 100,000 shares, worth approximately $8.09 million.
As published in their initiating research note from BTIG Research on May 16, 2024, Tscan Therapeutics Inc [TCRX] has been a Buy and the price target has been revised to $12. Analysts at Needham started covering the stock with ‘”a Buy”‘ outlook in a report released in mid May. As of June 22, 2023, Wedbush has initiated its “an Outperform” rating for TCRX.
Analyzing TCRX Stock Performance
On last trading session, Tscan Therapeutics Inc [NASDAQ: TCRX] rose 2.72% to $1.51. The stock’s lowest price that day was $1.465, but it reached a high of $1.53 in the same session. During the last five days, there has been a surge of approximately 2.03%. Over the course of the year, Tscan Therapeutics Inc shares have dropped approximately -74.54%. Shares of the company reached a 52-week high of $3.2100 on 01/03/25 and a 52-week low of $1.0200 on 04/09/25.
Support And Resistance Levels for Tscan Therapeutics Inc (TCRX)
According to the 24-hour chart, there is a support level at 1.4733, which, if violated, would cause prices to drop to 1.4367. In the upper region, resistance lies at 1.5383. The next price resistance is at 1.5667. RSI (Relative Strength Index) is 50.18 on the 14-day chart, showing neutral technical sentiment.
Is Tscan Therapeutics Inc subject to short interest?
Stocks of Tscan Therapeutics Inc saw a sharp steep in short interest on 2025-06-13 dropping by 34973.0 shares to 2.27 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 2.3 million shares. A decline of -1.54% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 2.95 of the overall float, the days-to-cover ratio (short ratio) decline to 2.95.
Which companies own the most shares of Tscan Therapeutics Inc (TCRX)?
In terms of Tscan Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 3 in the next 12 months, up nearly 104.08% from the previous closing price of $1.47. Analysts anticipate Tscan Therapeutics Inc stock to reach 3 by 2025, with the lowest price target being 3. In spite of this, 2 analysts ranked Tscan Therapeutics Inc stock as Buy at the end of 2025.
